0001209191-19-060041.txt : 20191211 0001209191-19-060041.hdr.sgml : 20191211 20191211163011 ACCESSION NUMBER: 0001209191-19-060041 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191209 FILED AS OF DATE: 20191211 DATE AS OF CHANGE: 20191211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Morl Christopher John CENTRAL INDEX KEY: 0001716821 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 191280079 MAIL ADDRESS: STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC STREET 2: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-09 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001716821 Morl Christopher John C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 0 1 0 0 Chief Business Officer Common Stock 2019-12-09 4 M 0 3387 3.95 A 3387 D Common Stock 2019-12-09 4 S 0 3387 55.00 D 0 D Common Stock 2019-12-10 4 M 0 11647 3.95 A 11647 D Common Stock 2019-12-10 4 S 0 11647 55.00 D 0 D Stock Option (Right to Buy) 3.95 2019-12-09 4 A 0 3387 0.00 A 2026-10-20 Common Stock 3387 222127 D Stock Option (Right to Buy) 3.95 2019-12-10 4 A 0 11647 0.00 A 2026-10-20 Common Stock 11647 210480 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of October 3, 2016, subject to continued service through such dates. /s/ Jeffrey M. Held, Attorney-in-Fact 2019-12-11